Article
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.
Antimicrobial agents and chemotherapy - 1 Oct 1998
Patick A K, Duran M, Cao Y, Shugarts D, Keller M R, Mazabel E, Knowles M, Chapman S, Kuritzkes D R, Markowitz M
Abstract excerpt
Nelfinavir mesylate (formerly AG1343) is a potent and selective inhibitor of human immunodeficiency virus (HIV) protease approved for the treatment of individuals infected with HIV. Nucleotide sequence analysis of protease genes from plasma HIV type 1 (HIV-1) RNA revealed a unique aspartic acid (...
Topics
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Drug Resistance
- Genotype
- HIV Protease
- HIV Protease Inhibitors
- HIV-1
- Humans
- Nelfinavir
- Phenotype
- Polymorphism, Genetic
- RNA, Viral